Cardior: Novo Nordisk to buy cardiac drug developer for up to $1.1B (NYSE:NVO)
Danish drugmaker Novo Nordisk (NVO) has agreed to acquire German cardiovascular disease drug developer Cardior Pharmaceuticals for up to EUR 1.025B, or $1.1B. Read more here.
Read full article »
Cardior is a Germany-based biopharmaceutical company that researches and develops RNA-dependent therapies for the treatment of heart diseases.
Read more